UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 14A

 

PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

 

Check the appropriate box:

 

☐ Preliminary Proxy Statement
☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐ Definitive Proxy Statement
☒ Definitive Additional Materials
☐ Soliciting Materials Pursuant to §240.14a-12

 

MyMD Pharmaceuticals, Inc.
(Name of Registrant as Specified in its Charter)

 

N/A
(Names of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (check the appropriate box):

 

☒ No fee required
☐ Fee paid previously with preliminary materials
☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

 

 

 

 

 

 

 

 

 

 

Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Akers Biosciences Charts.
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Akers Biosciences Charts.